Skip to main content
NVCR
NASDAQ Life Sciences

Novocure Narrows Q3 Loss to $10.4M, Turns Adjusted EBITDA Positive and Lifts Full-Year Revenue Outlook

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$15.34
Mkt Cap
$1.65B
52W Low
$9.82
52W High
$21.451
52W Position info
56% above low
Off High info
28% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

NVCR sits 56% above its 52-week low of $9.82.

Summary

Novocure posted a Q3 net loss of $10.4M while revenue rose 16% to $193.4M and gross margin expanded to 77%. Adjusted EBITDA came in positive at $15.7M — a meaningful swing for a company still burning cash on its income statement. Research, development and clinical study expenses were $58.1M. Management also raised full-year revenue and adjusted EBITDA guidance, lifting its 2026 view to revenue of $736M-$743M from $710M-$725M and adjusted EBITDA guidance to $24M-$34M from $0M-$15M, which is the part that matters most here. The quarter follows the October 1 Japanese approval of Optune Pax for locally advanced pancreatic cancer, adding a new commercial market on top of the core glioblastoma business. The offsetting backdrop is the June TRIDENT Phase 3 miss in earlier-line glioblastoma, so growth is leaning on existing indications and the pancreatic launch.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — Novocure raised 2026 revenue guidance to $736M-$743M from $710M-$725M and adjusted EBITDA guidance to $24M-$34M from $0M-$15M.

At the time of this announcement, NVCR was trading at $15.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.82 to $21.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

NVCR - Latest Insights

NVCR
Nov 09, 2026, 6:59 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $11.72 info
Change: -$2.23 (-16%) info
Market Cap: $1.37B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.25
Real-time Price: $11.72 info
Change: -$2.53 (-18%) info
Market Cap: $1.37B info
NVCR
Oct 29, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $11.72 info
Change: -$2.53 (-18%) info
Market Cap: $1.37B info
NVCR
Oct 01, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $11.72 info
Change: -$4.34 (-27%) info
Market Cap: $1.37B info
NVCR
Sep 01, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.70
Real-time Price: $11.72 info
Change: -$5.98 (-34%) info
Market Cap: $1.37B info